With over three years of experience in the medical communications business, Catarina holds a BSc. in Biomedical Sciences and a MSc. in Neurosciences. Apart from writing, she has been involved in patient-oriented translational and clinical research.
Abeona Therapeutics’ experimental gene therapy ABO-101 for people diagnosed with Sanfilippo syndrome type B has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA). The company is currently enrolling eligible patients ... Read more
Investigational enzyme replacement therapy BMN-250 successfully delivers the NAGLU enzyme — present in low levels in Sanfilippo type B patients — to key cells of the brain using different ... Read more